Back to the Pharma Future - The product feast has turned to famine-now where do companies turn? - BioPharm International

ADVERTISEMENT

Back to the Pharma Future
The product feast has turned to famine-now where do companies turn?


BioPharm International


In contrast to 1988, today's pharma marketplace is rife with pricing pressures, generic erosion, and increasing public, political, and regulatory scru-tiny. But, just recognize that the drug drought is the "disease" producing these troubling symptoms, and the cure becomes apparent. An industry that has gradually become reliant on biopharma and other third parties to stock its pipeline must continue to be creative in its business development approaches. Pharma must formulate new business models as well as new products. Its future depends on it.

Stan Bernard, MD and MBA, is president of Bernard Associates LLC, a management consulting firm that provides strategic planning, business development, and marketing services to health- care and pharmaceutical industry clients. He is also a senior fellow at The Wharton School of Business, where he has been teaching Pharmaceutical Management since 1991. Dr. Bernard can be reached at (908) 234-2704 or at
.


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

AbbVie/Shire Deal Officially Off
October 20, 2014
Amgen Sues Sanofi and Regeneron over Patent for mAb Targeting PCSK9
October 20, 2014
EMA Works to Speed Up Ebola Treatment
October 20, 2014
Lilly to Close Manufacturing Facility in Puerto Rico
October 17, 2014
BioReliance Introduces New Predictive Assays
October 17, 2014
Author Guidelines
Source: BioPharm International,
Click here